-
GSK invests $300m in 23andMe under drug development deal
pharmaceutical-technology
July 27, 2018
GlaxoSmithKline (GSK) has formed a multi-year alliance with genetics firm 23andMe to carry out research and development for new medicines and potential cures.
-
BMS collaborates with Tsinghua University for drug development
biospectrumasia
July 25, 2018
The collaboration is an expansion of an existing relationship between Bristol-Myers Squibb and Tsinghua University that began in 2012.
-
Analysis of New Drug R&D Strategies: Advantages of First-to-Market Drugs Shrinking while Latecomer me-better Drugs Surpassing
Mr. Nanguo
June 15, 2018
In the new drug development, pursuing the marketing of the first product of its variety is always the highest goal of pharmaceutical enterprises
-
WuXi AppTec to expand drug development testing services
biospectrumasia
April 23, 2018
The grand opening event was honored by the presence of state and local officials including State Senator Linda Greenstein
-
Doctor Calls for Alzheimer’s Boot Camps to Spur Drug Development
biospace
April 10, 2018
It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease.
-
STA Pharmaceutical sees rapid growth in MAH Programs in China
pharmaasia
December 27, 2017
Since the launch of the MAH pilot, STA has undertaken eight development programmes, and anticipates carrying on 10+ MAH projects in 2018.
-
Schizophrenia drugs market will be worth US$7.9 billion by 2022
pharmaasia
November 20, 2017
The report expects the schizophrenia market to be driven by improved drug delivery technologies, LAI availability and more patients seeking treatment.
-
New collaborative R&D report released by SCORR and Applied Clinical Trials
pharmaasia
October 25, 2017
SCORR Marketing and Applied Clinical Trials have released a new report on collaborative R&D in the drug development industry.
-
Industry puts building Big Biotechs, attracting 2,000 Big Pharma discovery scientists on wish list
fiercebiotech
August 31, 2017
The United Kingdom life sciences sector has called for (PDF) the government to make changes that help grow Big Biotechs and attract thousands of researchers. Industry leaders put together the wish list to influence an upcoming deal between the sector and
-
GlaxoSmithKline to cut 30 drug development programmes under plan to focus on four key areas
firstwordpharma
July 27, 2017
GlaxoSmithKline announced alongside its second-quarter results that it plans to cut more than 30 clinical and preclinical drug development programmes, whilst considering options for its rare diseases unit, as it looks to improve the efficiency of its phar